Jump to content

TFMBOX

Add links
From Wikipedia, the free encyclopedia

Not to be confused with BOx (psychedelics).
TFMBOX
Clinical data
Other names"Compound 5c"
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
Identifiers
  • 7-methoxy-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzoxepin-4-amine
CAS Number
Chemical and physical data
FormulaC12H14F3NO2
Molar mass261.244 g·mol−1
3D model (JSmol)
  • COc1cc2CC(N)CCOc2cc1C(F)(F)F
  • InChI=1S/C12H14F3NO2/c1-17-11-5-7-4-8(16)2-3-18-10(7)6-9(11)12(13,14)15/h5-6,8H,2-4,16H2,1H3
  • Key:NAOXZRLWFAOHAP-UHFFFAOYSA-N

TFMBOX is a putative serotonergic psychedelic of the phenethylamine and benzoxepin ("BOX") families.[1][2][3] It is the cyclized phenethylamine analogue of DOTFM and 2C-TFM in which the α carbon has been connected to the 2-methoxy group via an ethyl chain to form a benzoxepin ring system.[1][2]

The drug was assessed at and showed affinity for the serotonin 5-HT2A and 5-HT1A receptors, with Ki values of 340 nM and 1,300 nM, respectively.[2] Its affinity for the serotonin 5-HT2A receptor was about 15-fold lower than that of DOB and DOI, whereas its affinity for the serotonin 5-HT1A receptor was the same as that of DOI and was about half that of DOB.[2] TFMBOX also very weakly inhibited the reuptake of serotonin (IC50Tooltip half-maximal inhibitory concentration = 9,900 nM), but did not affect dopamine or norepinephrine reuptake (IC50 = >50,000–100,000 nM).[2] The drug fully substituted for LSD in rodent drug discrimination tests, albeit with about one-third of the potency of DOB and 2C-B.[2]

TFMBOX was first described in the scientific literature by Nick Cozzi, a student of David E. Nichols, by 1994.[2][3] Other "BOX" drugs that were assessed by the group include BOX (the cyclized analogue of 2C-H and DOH), BBOX (the cyclized analogue of 2C-B and DOB), and IBOX (the cyclized analogue of 2C-I and DOI).[2][3] However, BBOX and IBOX only partially substituted for LSD in drug discrimination tests.[2][3][4]

See also

[edit]

References

[edit]
  1. ^ a b Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. pp. 852–853. ISBN 978-3-03788-700-4. OCLC 858805226. Retrieved 31 January 2025.
  2. ^ a b c d e f g h i Monte AP, Marona-Lewicka D, Cozzi NV, Nelson DL, Nichols DE (1995). "Conformationally Restricted Tetrahydro-1-Benzoxepin Analogs of Hallucinogenic Phenethylamines". Medicinal Chemistry Research. 5 (651–663).
  3. ^ a b c d Cozzi NV (1994). Pharmacological studies of some psychoactive phenylalkylamines: Entactogens, hallucinogens, and anorectics (Ph.D. thesis). University of Wisconsin, Madison. Retrieved 15 April 2025 – via ProQuest.
  4. ^ Monte AP (August 1995). Structure-activity relationships of hallucinogens: Design, synthesis, and pharmacological evaluation of a series of conformationally restricted phenethylamines (Ph.D. thesis). Purdue University. Retrieved 15 April 2025 – via ProQuest.
[edit]


Retrieved from "https://en.wikipedia.org/w/index.php?title=TFMBOX&oldid=1292633883"